New Drug Effective Against Pancreatic Cancer

Wednesday, 21 Aug 2013 12:15 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Incyte Corp said a mid-stage trial of its experimental cancer treatment showed the drug, Jakafi, improved the survival rate of patients most likely to benefit from the treatment.
The company's shares rose 20 percent in premarket trade.
The six month survival rate of patients treated with Jakafi along with chemotherapy was 42 percent, compared with an 11 percent survival rate for those on placebo.
The drug, generically known as ruxolitinib, was tested in combination with chemotherapy drug, capecitabine, to improve the overall survival of patients with advanced pancreatic cancer, as compared to capecitabine alone.
The combination of Jakafi and capecitabine was generally well tolerated in the study.
Among the patients receiving the combination therapy, 12 percent discontinued treatment for an adverse event, compared with 20 percent patients who received capecitabine alone.
Incyte shares were up 20 percent to $32.50 in trading before the bell. They closed at $27 on Tuesday on the Nasdaq.
 

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Ebola Nurse Amber Vinson Free of Virus, Family Says

Thursday, 23 Oct 2014 08:23 AM

Amber Vinson, one of two nurses battling Ebola after contracting it from a patient at a Dallas hospital, is now free of  . . .

Drug Shows Promise Against Ankylosing Spondylitis

Thursday, 23 Oct 2014 08:18 AM

Swiss drugmaker Novartis said on Thursday two late-stage trials showed its drug secukinumab improved symptoms of ankylos . . .

Drug Companies Want Indemnity for Fast-Tracked Ebola Vaccines

Thursday, 23 Oct 2014 08:11 AM

Drugmakers are looking for some kind of indemnity from governments or multilateral agencies against possible losses or c . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved